33,800 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,800 shares of the company’s stock, valued at approximately $912,000.

Several other large investors have also bought and sold shares of MLYS. KBC Group NV bought a new stake in shares of Mineralys Therapeutics in the 1st quarter valued at about $33,000. Royal Bank of Canada raised its position in shares of Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock worth $56,000 after acquiring an additional 1,107 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in shares of Mineralys Therapeutics by 400.0% in the second quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after acquiring an additional 2,000 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after acquiring an additional 1,993 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after acquiring an additional 3,241 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Rodman sold 2,170 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.09, for a total value of $58,785.30. Following the completion of the sale, the insider directly owned 51,384 shares in the company, valued at approximately $1,391,992.56. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the completion of the sale, the chief executive officer directly owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 205,924 shares of company stock worth $5,364,551. 18.94% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Zacks Research downgraded shares of Mineralys Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $48.80.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $28.20 on Monday. The company has a market cap of $2.49 billion, a P/E ratio of -6.65 and a beta of 0.68. The stock has a 50 day simple moving average of $27.24 and a two-hundred day simple moving average of $27.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. Mineralys Therapeutics, Inc. has a fifty-two week low of $22.30 and a fifty-two week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). Research analysts forecast that Mineralys Therapeutics, Inc. will post -4.45 earnings per share for the current year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company’s research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.

Mineralys’ lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.